The figitumumab combination appeared more toxic , with more treatment-related grade 3/4 adverse events ( 75 % vs. 56 % ) , particularly hyperglycemia , diarrhea , and asthenia , as well as treatment-related serious adverse events ( 41 % vs. 15 % ) , and all-causality grade 5 adverse events ( 18 % vs. 8 % ) .